SecBot SecBot
SC 13G/A ·Filed Nov 9, 2026

KPTI

Karyopharm Therapeutics Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed7d 13h ago SEC0000886982-26-000549
Passive stake amendment
Actionable Insight • Neutral

Monitor for any further amendments or conversion to a 13D if Goldman Sachs increases its stake or changes investment intent. The current passive stake is minimal and unlikely to drive stock movement.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.0400
T+0 close · Nov 9, 2026 · via day close
Latest settled
−56.50%
T+1 · $0.0174 · next T+5 due 21h ago
Vs SPY
−56.13%
α at T+1
Latest observation
−17.21%
T+5 · FF3 residual α
  1. T+0 · Nov 9 $0.0400entry
  2. T+1 · 7d ago −56.50%α −56.13% · $0.0174
  3. T+5 · due 21h ago Pending
  4. T+5 · todayOpen
  5. T+20 · in 21d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Goldman Sachs filed an amended Schedule 13G disclosing a beneficial ownership of 203,129 shares (0.9%) of Karyopharm Therapeutics as of September 30, 2026. This is a routine passive stake update; the stake is very small relative to the company's market cap and represents no material change in investment intent.

Key Financial Metrics

Stake
0.9%
Stake Value
$203.1K
Investor
The Goldman Sachs Group, Inc.

Key Facts

  • Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed an amended Schedule 13G
  • Beneficial ownership: 203,129 shares (0.9%) of Karyopharm Therapeutics as of September 30, 2026
  • Stake value approximately $203,129 based on filing data
  • Filing is a routine passive stake update under Rule 13d-1(b)

Financial Impact

Stake of 203,129 shares (0.9%) valued at approximately $203,129

ownership

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0000886982-26-000549
Document: 0000886982-26-000549-index-headers.html0000886982-26-000549
Document: 0000886982-26-000549-index.html0000886982-26-000549
Document: 0000886982-26-000549.txt0000886982-26-000549

Track record

30 reports on KPTI

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 13 of 14 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
  2. Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
  3. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
  4. Nov 9, 20267d ago SC 13G/A Neutral 2/10 Viewing Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
  5. Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
  6. Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
  7. Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
  8. Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
  9. Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
  10. Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
Showing 10 of 30

US Market Status

Market Closed · Opens in 5h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026